Loading
G1 Therapeutics developed trilaciclib (Cosela), a CDK4/6 inhibitor given before chemotherapy to protect bone marrow, approved in 2021 for small-cell lung cancer; the company was acquired by Pharmacosmos in 2024.
G1 Therapeutics, based in Research Triangle Park, North Carolina, developed trilaciclib, an intravenous CDK4/6 inhibitor that briefly halts haematopoietic stem cells before chemotherapy so they are spared its damage. The FDA approved it as Cosela in February 2021 to reduce chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer; a phase 3 trial in triple-negative breast cancer (PRESERVE 2) did not improve survival. Pharmacosmos, the Danish iron-medicine company, acquired G1 in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Lerociclib is a CDK4/6 inhibitor from G1 Therapeutics developed in China by Genor Biopharma, in a phase 3 trial with letrozole for hormone receptor-positive breast cancer.
Trilaciclib is given as an infusion just before chemotherapy for small cell lung cancer to put the bone marrow's stem cells briefly to sleep, so fewer are killed and patients need fewer transfusions and growth factor injections.
Shares Trilaciclib, Small-cell lung cancer.
Shares CDK4/6, Small-cell lung cancer, Triple-negative breast cancer (TNBC).
Shares Trilaciclib, Small-cell lung cancer.
Shares CDK4/6 inhibitors, Small-cell lung cancer.
Shares CDK4/6, CDK4/6 inhibitors.
Shares CDK4/6, CDK4/6 inhibitors.